RD04

RD04 is an investigational small molecule being developed by NucMito Pharmaceuticals for the treatment of oncology-related conditions. Currently in the preclinical stage, RD04 is designed to target a nuclear receptor, a class of proteins that function as transcription factors to regulate gene expression in response to various ligands. While the specific nuclear receptor target and detailed mechanism of action have not been publicly disclosed, the drug is part of NucMito's research program focused on nuclear receptor biology and its role in tumor progression and metabolism. The candidate is listed in the company's pipeline as a treatment for oncology-related indications, following their lead programs targeting the Retinoid X Receptor (RXR) family.